Jazz Pharmaceuticals JAZZ shares ended the last trading session 6.6% higher at $170.82. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 1.6% loss over the past four weeks.

Strong uptake of low-sodium alternative of Xyrem, Xywav, during the first quarter and diversification of portfolio with completion of acquisition of GW Pharmaceuticals boosted investors' confidence.

Price and Consensus

This drugmaker is expected to post quarterly earnings of $4.02 per share in its upcoming report, which represents a year-over-year change of +8.4%. Revenues are expected to be $651.93 million, up 15.9% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For Jazz, the consensus EPS estimate for the quarter has been revised 1.7% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on JAZZ going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research